Terns Pharmaceuticals Inc (TERN) Q4 2025 Earnings Call Transcript

Why It Matters

The guidance underscores Geron’s ability to scale Rytelo’s commercial footprint while tightening costs, positioning the firm for sustainable growth in a high‑unmet‑need hematology market.

Key Takeaways

• Rytelo 2025 revenue $184M, 2026 guidance $220‑240M.
• Q4 demand grew 9%, accounts up 13% to 1,300.
• Gross‑to‑net deductions rose to 17.7% in 2025.
• Operating expenses projected $230‑240M in 2026, $20M lower.
• Cash $400M year‑end; $125M loan facility through July 2026.

Pulse Analysis

Rytelo’s emergence as a preferred second‑line therapy for lower‑risk myelodysplastic syndromes reflects a broader shift in hematology treatment paradigms. The drug’s inclusion in NCCN guidelines and its telomerase‑inhibition mechanism differentiate it from competitors such as luspatercept, which now occupies the first‑line space. By targeting an estimated 8,000 eligible second‑line patients, Geron taps a sizable market segment that has historically lacked effective options, creating a clear pathway for revenue expansion as clinicians adopt Rytelo earlier in treatment algorithms.

Financially, Geron delivered a 143% year‑over‑year increase in Rytelo net revenue, reaching $184 million in 2025, while maintaining operating expenses within its prior guidance band. The rise in gross‑to‑net deductions to 17.7% signals deeper penetration into 340B and GPO channels, a trade‑off that may boost volume despite margin pressure. Nonetheless, the company’s disciplined expense management—evidenced by a projected $20 million reduction in 2026 operating costs—and a robust cash position of $400 million provide ample runway to fund commercial initiatives without compromising financial stability.

Strategically, Geron is leveraging a three‑pronged commercial model that blends high‑volume community engagement, amplified digital outreach, and cross‑functional account management. Parallel medical‑affairs efforts focus on over ten investigator‑sponsored trials and real‑world evidence studies slated for 2026, aiming to deepen Rytelo’s data package and support potential label expansions. The ongoing IMPACT MF trial, with an interim analysis expected in late 2026, could unlock additional indications beyond MDS. Together, these initiatives, coupled with a cautious yet optimistic profitability outlook, suggest Geron is positioning itself as a long‑term hematology powerhouse.